Literature DB >> 30309894

Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.

Maria Katsarou1, Efstratios Stratikos2, Angeliki Chroni3.   

Abstract

Lipoprotein glomerulopathy (LPG) is a rare renal disease, characterized by lipoprotein thrombi in glomerular capillaries. A series of apoE mutations have been associated with LPG development. We previously showed that three mutants based on apoE3 sequence, in which an arginine was substituted by proline, are thermodynamically destabilized and aggregation-prone. To examine whether other LPG-associated apoE3 mutations induce similar effects, we characterized three nonproline LPG-associated apoE3 mutations, namely, R25C (apoEKyoto), R114C (apoETsukuba), and A152D (apoELasVegas). All three apoE3 variants are found to have significantly reduced helical content and to be thermodynamically destabilized, both in lipid-free and lipoprotein-associated form, and to expose a larger portion of hydrophobic surface to the solvent compared with WT apoE3. Furthermore, all three apoE3 variants are aggregation-prone, as shown by dynamic light-scattering measurements and by their enhanced capacity to bind the amyloid probe thioflavin T. Overall, our data suggest that the LPG-associated apoE3 mutations R25C, R114C, and A152D induce protein misfolding, which may contribute to protein aggregation in glomerular capillaries. The similar effects of both LPG-associated proline and nonproline mutations on apoE3 structure suggest that the thermodynamic destabilization and enhanced aggregation of apoE3 may constitute a common underlying mechanism behind the pathogenesis of LPG.
Copyright © 2018 Katsarou et al.

Entities:  

Keywords:  apolipoprotein E; apolipoproteins; dyslipedemias; kidney; mutations; physical biochemistry; thermodynamic stability

Mesh:

Substances:

Year:  2018        PMID: 30309894      PMCID: PMC6277168          DOI: 10.1194/jlr.M088732

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  45 in total

1.  Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity.

Authors:  M Sakatsume; M Kadomura; I Sakata; N Imai; D Kondo; Y Osawa; H Shimada; M Ueno; T Miida; S Nishi; M Arakawa; F Gejyo
Journal:  Kidney Int       Date:  2001-05       Impact factor: 10.612

2.  Helical structure, stability, and dynamics in human apolipoprotein E3 and E4 by hydrogen exchange and mass spectrometry.

Authors:  Palaniappan S Chetty; Leland Mayne; Sissel Lund-Katz; S Walter Englander; Michael C Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

3.  Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney.

Authors:  T Miyata; S Sugiyama; M Nangaku; D Suzuki; K Uragami; R Inagi; H Sakai; K Kurokawa
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

4.  A mechanism for lipid binding to apoE and the role of intrinsically disordered regions coupled to domain-domain interactions.

Authors:  Carl Frieden; Hanliu Wang; Chris M W Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-30       Impact factor: 11.205

5.  Probing the lipid-free structure and stability of apolipoprotein A-I by mutation.

Authors:  I N Gorshkova; K Liadaki; O Gursky; D Atkinson; V I Zannis
Journal:  Biochemistry       Date:  2000-12-26       Impact factor: 3.162

6.  Influence of Isoforms and Carboxyl-Terminal Truncations on the Capacity of Apolipoprotein E To Associate with and Activate Phospholipid Transfer Protein.

Authors:  Ioannis Dafnis; Jari Metso; Vassilis I Zannis; Matti Jauhiainen; Angeliki Chroni
Journal:  Biochemistry       Date:  2015-09-17       Impact factor: 3.162

7.  A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy.

Authors:  Masahiro Hagiwara; Kunihiro Yamagata; Tsuneaki Matsunaga; Yoh Arakawa; Joichi Usui; Yoshio Shimizu; Kumi Aita; Michio Nagata; Akio Koyama; Bo Zhang; Akira Mastunaga; Keigiro Saku; Takao Saito
Journal:  Nephrol Dial Transplant       Date:  2007-10-28       Impact factor: 5.992

Review 8.  A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy.

Authors:  Efstratios Stratikos; Angeliki Chroni
Journal:  Clin Exp Nephrol       Date:  2013-10-23       Impact factor: 2.801

9.  Molecular basis for increased risk for late-onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4.

Authors:  Letta Argyri; Ioannis Dafnis; Theodossis A Theodossiou; Donald Gantz; Efstratios Stratikos; Angeliki Chroni
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

10.  Renal apolipoproteins in nephrotic rats.

Authors:  H van Goor; M L van der Horst; J Atmosoerodjo; J A Joles; A van Tol; J Grond
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

View more
  7 in total

1.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

3.  Diverse proteins aggregate in mild cognitive impairment and Alzheimer's disease brain.

Authors:  Devin Kepchia; Ling Huang; Richard Dargusch; Robert A Rissman; Maxim N Shokhirev; Wolfgang Fischer; David Schubert
Journal:  Alzheimers Res Ther       Date:  2020-06-19       Impact factor: 6.982

4.  Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.

Authors:  Mingxin Yang; Qinjie Weng; Xiaoxia Pan; Hafiz Muhammad Jafar Hussain; Shuwen Yu; Jing Xu; Xialian Yu; Yunzi Liu; Yuanmeng Jin; Chunli Zhang; Xiao Li; Hong Ren; Nan Chen; Jingyuan Xie
Journal:  Mol Genet Genomic Med       Date:  2020-05-22       Impact factor: 2.183

5.  Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.

Authors:  Hongyan Wu; Jing Yang; Yun-Qiang Liu; Song Lei; Mei Yang; Zhi Yang; Yuan Yang; Zhangxue Hu
Journal:  J Transl Med       Date:  2021-03-04       Impact factor: 5.531

6.  A novel apolipoprotein E mutation, ApoE Ganzhou (Arg43Cys), in a Chinese son and his father with lipoprotein glomerulopathy: two case reports.

Authors:  Runxiu Wang; Chengbo Zhao; Wen Chen; Zhiping Liu; Fuhua Xie
Journal:  J Med Case Rep       Date:  2022-02-23

7.  Lipoprotein glomerulopathy associated with the Osaka/Kurashiki APOE variant: two cases identified in Latin America.

Authors:  Joaquim Nelito da Silveira-Neto; Guilherme Jinson de Oliveira Ahn; Precil Diego Miranda de Menezes Neves; Vinicius Augusto Ferreira Baptista; Stanley de Almeida Araújo; David Campos Wanderley; Andréia Watanabe; Elieser Hitoshi Watanabe; Neide Missae Murai; Eny Maria Goloni Bertollo; Osvaldo Merege Vieira-Neto; Márcio Dantas; Sergio Ricardo de Antônio; Roberto Silva Costa; Maria Alice Sperto Ferreira Baptista; Miguel Moysés-Neto; Luiz Fernando Onuchic
Journal:  Diagn Pathol       Date:  2021-07-26       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.